In terms of the implications for current clinical oncology, our study indicates that MUC2++/+++ ovarian cancer cases should be closely followed up with specific attention to their local immunosuppressive status and that treatment with appropriate immunomodulators, such as COX-2 inhibitors, IL2 and IFNγ, which favor the M1 differentiation of TAMs, should be evaluated. This evidence concerns the gene PTGS2 and ovarian carcinoma.